FLT3 inhibitors in acute myeloid leukemia

Expert Review of Hematology

Volumn 1, Issue 2, 2008, Pages 153-160

  el Shami, Khaled ^a   Stone, Richard M ^b   Smith, b Douglas ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

acute myeloid leukemia; FLT3; inhibitor; prognosis; tyrosine kinase

Indexed keywords

CD135 ANTIGEN; FLT3 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL; DRUG ANTAGONISM; ENZYMOLOGY; HUMAN; PROGNOSIS; REVIEW;

ANIMALS; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; PROGNOSIS; PROTEIN KINASE INHIBITORS;

EID: 79954442787     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.1.2.153     Document Type: Article

References (72)

1. van der Geer P, Hunter T, Lindberg RA. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu. Rev. Cell Biol. 10, 251–337 (1994).
2. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 103 (2), 211–225 (2000).
3. Ben-Neriah Y, Daley GQ, Med-Masson AM et al. The chronic myelogenous leukemia specific p210 protein is the product of bcr/abl hybrid gene. Science 233 (4760), 212–214 (1986).
4. Cools J, DeAngelo DJ, Gotlieb J et al. A tyrosine kinase created by the fusion of the PDGFR and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348 (13), 1201–1241 (2003).
5. Kralovics R, Passamonti F, Buser AS et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352 (17), 1779–1790 (2005).
6. Levine RL, Wadleigh M, Cools J et al. Activating mutations in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (4), 387–397 (2005).
7. James C, Ugo V, Le Couedic JP et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 434 (7037), 1144–1148 (2005).
8. Gilliland DG. Molecular genetics of human leukemia. Leukemia 1 (Suppl.), S7 –S12 (1998).
9. Gilliland DG, Griffin JD. The role of FLT3 in hematopoiesis and leukemia. Blood 100 (5), 1532–1542 (2002).
10. Rosnet O, Schiff C, Pebusque MJ et al. Human FLT/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood 82 (4), 1110–1119 (1993).
11. + human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc. Natl Acad. Sci. USA 91 (2), 459–463 (1994).
12. Hannum C, Culpepper J, Campbell D et al. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of hematopoietic stem cells and is encoded by variant RNAs. Nature 368 (6472), 643–648 (1994).
13. Lyman SD, James L, Lee Y et al. Essential role of human homologue of murine flt3 ligand: a growth factor for early hematopoietic progenitor cells. Blood 83 (10), 2795–2801 (1994).
14. Dosil M, Wang S, Lemischka IR. Mitogenic signaling and substrate specificity of FLK2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells. Mol. Cell Biol. 13 (10), 6572–6585 (1993).
15. Rosnet O, Buhring HJ, deLapeyriere O et al. Expression and signal transduction of the FLT3 tyrosine kinase receptor. Acta Hematol. 95 (3–4), 218–223 (1996).
16. Lavagna-Sevenier C, Marchetto S, Birnbaum D et al. FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates. Leukemia 12 (3), 301–310 (1998).
17. Lavagna-Sevenier C, Marchetto S, Birnbaum D et al. The CBL-related protein CBLB participates in FLT3 and interleukin-7 receptor signal transduction in pro-B cells. J. Biol. Chem. 273 (24), 14962–14967 (1998).
18. Zhang S, Mantel C, Broxmeyer HE. Flt3 signaling involves tyrosyl phosphorylation of SPH-2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells. J. Leukoc. Biol. 65 (3), 372–380 (1999).
19. Marchetto S, Fournier E, Beslu N et al. SHC and SHIP phosphorylation and interaction in response to activation of FLT3 receptor. Leukemia 13 (9), 1374–1382 (1999).
20. Zhang S, Fukuda S, Lee Y et al. Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling. J. Exp. Med. 192 (5), 719–729 (2000).
21. + human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc. Natl Acad. Sci. USA 91 (2), 459–463 (1993).
22. Mackarehtschian K, Hardin JD, Moore KA et al. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity 3 (1), 147–161 (1995).
23. McKenna HJ, Stocking KL, Miller RE et al. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 95 (11), 3489–3497 (2000).
24. Ray RJ, Paige CJ, Furlonger C et al. Flt3 ligand supports the differentiation of early B cell progenitors in the presence of interleukin-11 and interleukin-7. Eur. J. Immunol. 26 (7), 1504–1510 (1996).
25. Veiby OP, Jacobson FW, Cui L et al. The flt3 ligand promotes the survival of hematopoietic progenitor cells with myeloid as well as B lymphoid potential. Suppression of apoptosis and counteraction by TNF-α and TNF-β. J. Immunol. 157 (7), 2953–2960 (1996).
26. Broxmeyer HE, Lu L, Cooper S et al. Flt3 ligand stimulates/costimulates the growth of myeloid stem/progenitor cells. Exp. Hematol. 23 (10), 1121–1129 (1996).
27. Hirayama F, Lyman SD, Clark SC et al. The flt3 ligand supports proliferation of lymphohematopoietic progenitors and early B-lymphoid progenitors. Blood 85 (7), 1762–1768 (1995).
28. + hematopoietic stem cells capable of multilineage engrafting NOD/SCID mice express flt3: distinct flt3 and c-kit expression and response patterns on mouse and candidate human hematopoietic stem cells. Blood 102 (3), 881–886 (2003).
29. Kiyoi H, Ohno R, Ueda R et al. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene 21 (16), 2555–2563 (2002).
30. Abu-Duhier FM, Goodeve AC, Wilson GA et al. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukemia. Br. J. Hematol. 113 (4), 983–988 (2001).
31. Bacher U, Haferlach C, Kern W et al. Prognostic relevance of FLT3-TDK mutations in AML: the combination matters – an analysis of 3082 patients. Blood 111 (5), 2527–2537 (2008).
32. Yamamoto Y, Kiyoi H, Nakano Y et al. Activation mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97 (8), 2434–2439 (2001).
33. Kiyoi H, Towatari M, Yokota S et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 12 (9), 1333–1337 (1998).
34. Mizuki M, Fenski R, Halfter H et al. FLt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by Ras and STAT5 pathways. Blood 96 (12), 3907–3914 (2000).
35. Mizuki M, Schwabe J, Steur C et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood 101 (8), 3164–3173 (2003).
36. Scheijen B, Ngo HT, Kang H et al. FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins. Oncogene 23 (19), 3338–3349 (2004).
37. Choudhary C, Schwable J, Brandts C et al. AML-associated Flt3 kinase domain mutations show signal transduction differences in comparison to Flt3 ITD mutations. Blood 106 (1), 265–273 (2005).
38. Stock W, Najib K, Moser BK et al. High incidence of FLT3 mutation in adults with acute promyelocytic leukemia (APL): correlation with diagnostic features and treatment outcome. J. Clin. Oncol. 26 (2008) (Abstract 7002).
39. Kiyoi H, Naoe T, Yokota S et al. Internal tandem repeat duplications of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia 11 (9), 1447–1452 (1997).
40. Arrigoni P, Beretta C, Silvestri D et al. FLT3 internal tandem repeat duplication in childhood acute myeloid leukemia: association of hyperleukocytosis in acute promyelocytic leukemia. Br. J. Hematol. 120 (1), 89–92 (2003).
41. Noguera NI, Breccia M, Divona M et al. Alterations of FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia 16 (11), 2185–2189 (2002).
42. Shih LY, Kuo MC, Liang DC et al. Internal tandem repeat duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) in acute promyelocytic leukemia. Cancer 98 (6), 1206–1216 (2003).
43. Schlenk RF, Germing U, Hartmann F et al. High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. Leukemia 19 (6), 978–983 (2005).
44. Levis M, Small D. ITDoes matter in leukemia. Leukemia 17 (9), 1738–1752 (2003).
45. Murphy KM, Levis M, Hafez MJ et al. Detection of FLT3 internal tandem repeat duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J. Mol. Diagn. 5 (2), 96–102 (2003).
46. Mishinchi S, Woods WG, Stirewalt DL et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 97 (1), 89–94 (2001).
47. Froeling S, Schlenk RF, Breitruck J et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML study group. Blood 100 (13), 4372–4380 (2002).
48. Scholl S, Theuer C, Scheble V et al. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 years with acute myeloid leukemia. Eur. J. Hematol. 80 (3), 208–215 (2008).
49. Gale RE, Green C, Allen C et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 111 (5), 2776–2784 (2008).
50. Adjei AA, Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy. J. Clin. Oncol. 23 (23), 5386–5403 (2005).
51. Li Y, Li H, Wang MN et al. Suppression of leukemia expressing wild-type or ITD-mutant Flt3 receptor by a fully human anti-FLT3 neutralizing antibody. Blood 104 (4), 1137–1144 (2004).
52. Traxler P, Bold G, Buchdunger E et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med. Res. Rev. 21 (6), 499–512 (2001).
53. Fiedler W, Mesters R, Tinnefeld H et al. A Phase II clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 102 (8), 2763–2767 (2003).
54. Giles FJ, Cooper MA, Silverman L et al. Phase II study of SU5416-a small molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor- in patients with refractory myeloproliferative diseases. Cancer 97 (8), 1920–1928 (2003).
55. O’Farrell AM, Yuen HA, Smilich B et al. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. Leuk. Res. 28 (7), 679–689 (2004).
56. Levis M, Small D. Small molecule FLT3 tyrosine kinase inhibitors. Curr. Pharm. Des. 10 (11), 1183–1193 (2004).
57. Fiedler W, Serve H, Dohner H et al. A Phase I study of SU-11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105 (5), 986–993 (2005).
58. Yee KW, Schittenhelm M, O’Farrell AM et al. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT ITD-positive leukemic cells. Blood 104 (13), 4202–4209 (2004).
59. Weisberg E, Boulton C, Kelly LM et al. Inhibition of mutant FLT3 receptors in leukemia cells by small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 1 (5), 433–443 (2002).
60. Stone RM, Fischer T, Paquette R et al. Phase IB study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed adult patients (pts) with acute myeloid leukemia (AML) under age 61 (abstract). Blood (ASH Annual Meeting Abstracts) 108, 157 (2006).
61. Stone RM, DeAngrlo DJ, Klimek V et al. Patients with acute myeloid leukemia and activating mutation in FL3 respond to small molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 105 (1), 54–60 (2005).
62. Levis M, Allebach J, Tse KF et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 99 (11), 3885–3891 (2002).
63. Smith BD, Levis M, Beran M et al. Single agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed acute myeloid leukemia. Blood 103 (10), 3669–3676 (2004).
64. Levis M, Pham R, Smith BD et al. In vitro studies of FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood 104 (4), 1145–1150 (2004).
65. Kelly LM, Yu JC, Boulton CL et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell 1 (5), 421–432 (2002).
66. Pandey A, Volkots DL, Seroogy JM et al. Identification of orally active, potent, and selective 4-piper-azinylquinazoline as antagonists of platelet-derived growth factor receptor tyrosine kinase family. J. Med. Chem. 45 (17), 3772–3793 (2002).
67. De Angelo D, Stone RM, Heaney ML et al. Phase 1 clinical results of tandutinib (MLN518), a novel FLT3 antagonist in patients with acute myelogenous leukemia or high risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood 108 (12), 3674–3681 (2006).
68. De Angelo D, Stone R, Heaney M et al. Phase II evaluation of the tyrosine kinase inhibitor MLN518 in patients with acute myeloid leukemia (AML) bearing a FLT3 internal tandem duplication (ITD) mutation. Blood 104 (11) (2004) (Abstract 496).
69. Li L, Piloto O, Nguyen HB et al. Knock-in of an internal tandem repeat duplication mutation into murine FLT3 confers myeloproliferative disease in mouse model. Blood 111 (7), 3849–58 (2008)
70. Shah NP, Nicoll JM, Nagar B et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI-571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2 (2), 117–125 (2002).
71. Cools J, Mentens N, Furet P et al. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res. 64 (18), 6385–6389 (2004).
72. Bagrintseva K, Schwab R, Kohl TM et al. Mutations in the tyrosine kinase domain of Flt3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in Flt3-ITD-transformed hematopoietic cells. Blood 103 (6), 2266–2275 (2004).